📣 VC round data is live. Check it out!

Thermo Fisher Scientific Valuation Multiples

Discover revenue and EBITDA valuation multiples for Thermo Fisher Scientific and similar public comparables like Intuitive Surgical, Abbott, Danaher, Siemens and more.

Thermo Fisher Scientific Overview

About Thermo Fisher Scientific

Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year-end 2024 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (the remainder).


Founded

1956

HQ

United States

Employees

125.0K

Financials (LTM)

Revenue: $46B
EBITDA: $12B

EV

$223B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Thermo Fisher Scientific Financials

Thermo Fisher Scientific reported last 12-month revenue of $46B and EBITDA of $12B.

In the same LTM period, Thermo Fisher Scientific generated $19B in gross profit, $12B in EBITDA, and $9B in net income.

Revenue (LTM)


Thermo Fisher Scientific P&L

In the most recent fiscal year, Thermo Fisher Scientific reported revenue of $45B and EBITDA of $12B.

Thermo Fisher Scientific is profitable as of last fiscal year, with gross margin of 41%, EBITDA margin of 26%, and net margin of 19%.

See analyst estimates for Thermo Fisher Scientific
LTMLast FY202320242025202620272028
Revenue$46B$45B$43B$43B$45B
Gross Profit$19B$18B$17B$18B$18B
Gross Margin42%41%40%41%41%
EBITDA$12B$12B$11B$12B$12B
EBITDA Margin25%26%26%27%26%
EBIT Margin23%23%17%18%18%
Net Profit$9B$9B$6B$6B$7B
Net Margin19%19%14%15%15%
Net Debt-$30B---

Financial data powered by Morningstar, Inc.

Thermo Fisher Scientific Stock Performance

Thermo Fisher Scientific has current market cap of $183B, and enterprise value of $223B.

Market Cap Evolution


Thermo Fisher Scientific's stock price is $492.51.

Thermo Fisher Scientific share price increased by 2.8% in the last 30 days, and by 22.3% in the last year.

Thermo Fisher Scientific has an EPS (earnings per share) of $23.25.

See more trading valuation data for Thermo Fisher Scientific
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$223B$183B1.1%2.8%-5.5%22.3%$23.25

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Thermo Fisher Scientific Valuation Multiples

Thermo Fisher Scientific trades at 4.9x EV/Revenue multiple, and 19.2x EV/EBITDA.

See NTM and 2027E valuation multiples for Thermo Fisher Scientific

EV / Revenue (LTM)


Thermo Fisher Scientific Financial Valuation Multiples

As of May 30, 2026, Thermo Fisher Scientific has market cap of $183B and EV of $223B.

Thermo Fisher Scientific has a P/E ratio of 20.6x.

LTMLast FY202320242025202620272028
EV/Revenue4.9x5.0x5.2x5.2x5.0x
EV/EBITDA19.2x19.4x20.1x19.3x19.4x
EV/EBIT21.2x22.1x30.5x28.9x27.5x
EV/Gross Profit11.7x12.2x13.0x12.6x12.2x
P/E20.6x21.2x30.5x28.9x27.3x
EV/FCF33.4x35.2x32.2x30.7x35.4x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Thermo Fisher Scientific Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Thermo Fisher Scientific Margins & Growth Rates

Thermo Fisher Scientific grew revenue by 7% and EBITDA by 7% in the last fiscal year.

In the most recent fiscal year, Thermo Fisher Scientific reported gross margin of 41%, EBITDA margin of 26%, and net margin of 19%.

See estimated margins and future growth rates for Thermo Fisher Scientific

Thermo Fisher Scientific Margins

Last FY202420252026202720282029
Gross Margin41%41%41%42%
EBITDA Margin26%27%26%26%
EBIT Margin23%18%18%23%
Net Margin19%15%15%19%
FCF Margin14%17%14%15%

Thermo Fisher Scientific Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth7%0%4%7%
Gross Profit Growth9%4%3%9%
EBITDA Growth7%4%(0%)7%
EBIT Growth10%5%5%37%
Net Profit Growth7%6%6%38%
FCF Growth13%5%(13%)14%

Data powered by FactSet, Inc. and Morningstar, Inc.

Thermo Fisher Scientific Operational KPIs

Thermo Fisher Scientific's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.1M for the same period.

Thermo Fisher Scientific's Rule of 40 is 33% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Thermo Fisher Scientific's Rule of X is 44% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Thermo Fisher Scientific
LTMLast FY202320242025202620272028
Rule of 4032%33%---
Bessemer Rule of X41%44%---
Revenue per Employee-$0.4M---
Opex per Employee-$0.1M---
R&D Expenses to Revenue3%3%3%3%3%
Opex to Revenue-23%23%23%23%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Thermo Fisher Scientific Competitors

Thermo Fisher Scientific competitors include Intuitive Surgical, Abbott, Danaher, Siemens, Stryker, Medtronic, Boston Scientific, Hoya, Edwards Lifesciences and Roche.

Most Thermo Fisher Scientific public comparables operate across Laboratory Services, Medical Devices, Medical Supplies, BioTech, DeepTech and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Intuitive Surgical14.5x13.6x33.5x30.8x
Abbott4.0x3.8x14.6x14.2x
Danaher5.8x5.7x18.5x18.0x
Siemens3.0x2.9x15.0x16.4x
Stryker5.1x5.0x17.9x17.4x
Medtronic3.4x3.2x11.8x11.2x
Boston Scientific4.1x3.9x13.1x12.6x
Hoya9.6x8.8x27.5x23.2x

This data is available for Pro users. Sign up to see all Thermo Fisher Scientific competitors and their valuation data.

Start Free Trial

Thermo Fisher Scientific M&A Activity

Thermo Fisher Scientific has acquired 28 companies to date.

Last acquisition by Thermo Fisher Scientific was on October 29th 2025. Thermo Fisher Scientific acquired Clario for $9B (EV/Revenue multiple of ).

See M&A valuation multiples

Latest Acquisitions by Thermo Fisher Scientific

Clario
Solventum (purification & filtration unit)
Olink
CorEvitas
Description
Clario is a provider of integrated clinical trial technologies encompassing cardiac safety monitoring through ECG services, electronic clinical outcome assessments via the MyCap platform, medical imaging core lab analysis, respiratory endpoints with handheld spirometers, and precision motion tracking using wearable sensors. The company delivers software platforms, connected devices, and AI-driven analytics to support site-based, hybrid, and decentralized trial models worldwide. Clario serves pharmaceutical sponsors, biotechnology firms, and contract research organizations across therapeutic areas including oncology, neurology, and cardiology. Headquartered in Basel, Switzerland, with key offices in Philadelphia, London, and Singapore, it maintains regulatory compliance in over 100 countries and operates a global network of over 50 sites for data collection and evidence generation.
-
Olink Holding AB is a Stockholm-headquartered proteomics company accelerating biomarker discovery across diseases like oncology and cardiology. Its platform, deployed in over 100 biopharma firms and academic labs, enables high-throughput protein analysis via proximity extension assay technology. Olink's products include Explore and Target 96 panels measuring thousands of proteins from small samples. Listed on Nasdaq Stockholm since 2020, it supports precision medicine research globally.
CorEvitas is a Waltham, Massachusetts-headquartered provider of real-world evidence through registry data and analytics for biopharmaceutical firms. Formerly known as Corrona and founded in 2000, it manages six autoimmune disease registries in the USA, Canada, and Japan, gathering data from more than 400 investigator sites on clinical outcomes and patient-reported measures. The company supports safety surveillance for 14 drug approvals and post-authorization studies.
HQ CountryUnited StatesUnited StatesSwedenUnited States
HQ City
Philadelphia, PA
-
Uppsala
Boston, MA
Deal Date29 Oct 202525 Feb 202517 Oct 20236 Jul 2023
Valuation$9B$4B$3B$910M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Thermo Fisher Scientific acquisitions and their M&A valuation multiples.

Start Free Trial

Thermo Fisher Scientific Investment Activity

Thermo Fisher Scientific has invested in 3 companies to date.

Latest investment by Thermo Fisher Scientific was on December 4th 2024. Thermo Fisher Scientific invested in miDiagnostics in their $31M Series D round (EV/Revenue multiple of ).

See VC round multiples

Latest Investments by Thermo Fisher Scientific

miDiagnostics
CytoReason
WuXi Diagnostics
Description
miDiagnostics is a Belgian medtech company developing microfluidic disposable tests using finger-prick blood samples. The platform detects biomarkers including cells, proteins, nucleic acids, and small molecules for point-of-care diagnostics in cardiology and oncology. Products like the miLab reader process samples in 15 minutes, targeting primary care clinics and pharmacies across Europe. The Ghent-headquartered firm collaborates with Philips for cartridge manufacturing.
CytoReason is a Tel Aviv-based AI company building cell-centered computational models of human tissues for disease simulation. Its platform analyzes multi-omics data from pharma partners like AstraZeneca to predict drug responses in immunology and fibrosis. Founded in 2017, CytoReason shortens R&D timelines through tissue-by-tissue, cell-by-cell modeling for rheumatoid arthritis and other indications.
WuXi Diagnostics is a Wuxi-based innovator in precision diagnostic products and clinical insights for global healthcare. It develops testing solutions for diseases through advanced platforms, accessible at wuxidiagnostics.com.
HQ CountryBelgiumIsraelChina
HQ City
Leuven
Tel Aviv
Shanghai
Deal Date4 Dec 202417 Jul 202423 Feb 2021
RoundSeries DSeries BSeries B
Raised$31M$80M$150M
InvestorsAlychlo; Pamica AB; Thermo Fisher Scientific; VMF InvestAstarc Ventures; NVIDIA; OurCrowd; Pfizer; Thermo Fisher ScientificABC International; CCBI Tech Venture; Shiyu Capital; Sunland Capital; Thermo Fisher Scientific; YF Capital
Valuationundisclosed$500Mundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Thermo Fisher Scientific investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Thermo Fisher Scientific

When was Thermo Fisher Scientific founded?Thermo Fisher Scientific was founded in 1956.
Where is Thermo Fisher Scientific headquartered?Thermo Fisher Scientific is headquartered in United States.
How many employees does Thermo Fisher Scientific have?As of today, Thermo Fisher Scientific has over 125K employees.
Who is the CEO of Thermo Fisher Scientific?Thermo Fisher Scientific's CEO is Marc N. Casper.
Is Thermo Fisher Scientific publicly listed?Yes, Thermo Fisher Scientific is a public company listed on NYSE.
What is the stock symbol of Thermo Fisher Scientific?Thermo Fisher Scientific trades under TMO ticker.
When did Thermo Fisher Scientific go public?Thermo Fisher Scientific went public in 1972.
Who are competitors of Thermo Fisher Scientific?Thermo Fisher Scientific main competitors include Intuitive Surgical, Abbott, Danaher, Siemens, Stryker, Medtronic, Boston Scientific, Hoya, Edwards Lifesciences, Roche.
What is the current market cap of Thermo Fisher Scientific?Thermo Fisher Scientific's current market cap is $183B.
What is the current revenue of Thermo Fisher Scientific?Thermo Fisher Scientific's last 12 months revenue is $46B.
What is the current revenue growth of Thermo Fisher Scientific?Thermo Fisher Scientific revenue growth (NTM/LTM) is 6%.
What is the current EV/Revenue multiple of Thermo Fisher Scientific?Current revenue multiple of Thermo Fisher Scientific is 4.9x.
What is the current EBITDA of Thermo Fisher Scientific?Thermo Fisher Scientific's last 12 months EBITDA is $12B.
What is Thermo Fisher Scientific's EBITDA margin?Thermo Fisher Scientific's last 12 months EBITDA margin is 25%.
What is the current EV/EBITDA multiple of Thermo Fisher Scientific?Current EBITDA multiple of Thermo Fisher Scientific is 19.2x.
What is the current FCF of Thermo Fisher Scientific?Thermo Fisher Scientific's last 12 months FCF is $7B.
What is Thermo Fisher Scientific's FCF margin?Thermo Fisher Scientific's last 12 months FCF margin is 15%.
What is the current EV/FCF multiple of Thermo Fisher Scientific?Current FCF multiple of Thermo Fisher Scientific is 33.4x.
How many companies Thermo Fisher Scientific has acquired to date?As of May 2026, Thermo Fisher Scientific has acquired 27 companies.
What was the largest acquisition by Thermo Fisher Scientific?$17B acquisition of PharmaFluidics on 2nd November 2021 was the largest M&A Thermo Fisher Scientific has done to date.
What companies Thermo Fisher Scientific acquired?Thermo Fisher Scientific acquired PharmaFluidics, Thermo Fisher Scientific (PPD clinical research unit), Life Technologies, Clario, Patheon, FEI Company, Solventum (purification & filtration unit), Olink, The Binding Site Group, Peprotech, Inc, and 17 other companies.
In how many companies Thermo Fisher Scientific has invested to date?As of May 2026, Thermo Fisher Scientific has invested in 3 companies.
What was the last Thermo Fisher Scientific investment?On 4th December 2024 Thermo Fisher Scientific invested in miDiagnostics, participating in a $31M Series D round, alongside Alychlo, Pamica AB, and VMF Invest.
In what companies Thermo Fisher Scientific invested in?Thermo Fisher Scientific invested in WuXi Diagnostics, CytoReason, and miDiagnostics.

See public comps similar to Thermo Fisher Scientific

Lists including Thermo Fisher Scientific

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial